ArticleBritish journal of clinical pharmacology2009
Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders.
Article in British journal of clinical pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults.Nature medicine · 2025 · on this mapPooled it
- Physical Activity and Its Impact on Cardiometabolic Disorders.Handbook of experimental pharmacology · 2026Review
- GLP-1 and Its Role in Glycogen Production: A Narrative Review.Biomedicines · 2025Review
- Pharmacotherapy of obesity: an update on the available medications and drugs under investigation.EClinicalMedicine · 2023Review
- Protein sparing therapies in acute illness and obesity: a review of George Blackburn's contributions to nutrition science.Metabolism: clinical and experimental · 2018Review
- Feeling the pressure: (patho) physiological mechanisms of weight gain and weight loss in humans.Hypertension research : official journal of the Japanese Society of Hypertension · 2017Review
- Obesity: Current and potential pharmacotherapeutics and targets.Pharmacology & therapeutics · 2017Review
- Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity via Activation of Farnesyl X Receptor.Frontiers in pharmacology · 2016Article
- The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA.PharmacoEconomics · 2015Review
- Characterization of the 5-HT2C receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity.Pharmacology research & perspectives · 2015Article
- Analysing coverage decision-making: opening Pandora's box?The European journal of health economics : HEPAC : health economics in prevention and care · 2014Article
- Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity.Diabetes, metabolic syndrome and obesity : targets and therapy · 2014Review
- Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet.Diabetes, metabolic syndrome and obesity : targets and therapy · 2014Article
- Acute behavioural effects of bupropion and naltrexone, alone and in combination, in non-deprived male rats presented with palatable mash.Psychopharmacology · 2013Article
- Pharmacotherapy for childhood obesity: present and future prospects.International journal of obesity (2005) · 2013Review
- Anti-obesity drugs: past, present and future.Disease models & mechanisms · 2012Review
- Rhein Reduces Fat Weight in db/db Mouse and Prevents Diet-Induced Obesity in C57Bl/6 Mouse through the Inhibition of PPARγ Signaling.PPAR research · 2012Article
- The utility of animal models to evaluate novel anti-obesity agents.British journal of pharmacology · 2011Review
- Sibutramine on cardiovascular outcome.Diabetes care · 2011Review
- Central and peripheral molecular targets for antiobesity pharmacotherapy.Clinical pharmacology and therapeutics · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a major cause of morbidity and mortality through cardio- and cerebrovascular diseases and cancer. The metabolic consequences of obesity include dyslipidaemia, hypertension, proinflammatory atherogenesis, pre-diabetes and Type 2 diabetes. For a significant proportion of patients, pharmacotherapy to tackle obesity is required as adjunctive support to diet, exercise and lifestyle modification. To this end, the pharmaceutical industry is pursuing many novel drug targets. Although this view is probably not justified, the recent tribulations of rimonabant have created a perception that the regulatory bar for the approval of antiobesity drugs has been raised. Although >5% of placebo-subtracted weight loss maintained over 1 year is the primary efficacy end-point, it is improvements in cardiovascular risk factors that the Food and Drug Administration (FDA) and European Medicines Agency (EMEA) require to grant approval. Safety aspects are also critical in this indication. Many companies are now switching development of their antiobesity drug candidates into other metabolic disorders. Type 2 diabetes is accepted by the industry and FDA, but not EMEA, as the most appropriate alternative. On the other hand, improvements in plasma lipids produced by antiobesity drugs are moderate compared with established therapies, suggesting dyslipidaemia is not a viable development option. Metabolic Syndrome is not accepted by FDA or EMEA as a discrete disease and the agencies will not licence antiobesity drugs for its treatment. The regulatory environment for antiobesity drugs and the spectrum of indications for which they can be approved could change dramatically if positive data for sibutramine emerge from the SCOUT outcome trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.